References
- Al-Saeedi, A. H., Al-Ghafri, M. T. H., & Hossain, M. A. (2016). Comparative evaluation of total phenols, flavonoids content and antioxidant potential of leaf and fruit extracts of Omani Ziziphus jujuba L. Pacific Science Review A: Natural Science and Engineering, 18(1), 78–83. https://doi.org/https://doi.org/10.1016/j.psra.2016.09.001
- Behmard, E., & Barzegari, E. (2020). Insights into resistance mechanism of hepatitis C virus nonstructural 3/4A protease mutant to boceprevir using umbrella sampling simulation study. Journal of Biomolecular Structure & Dynamics, 38(7), 1938–1945. https://doi.org/https://doi.org/10.1080/07391102.2019.1621212
- Blach, S., Zeuzem, S., Manns, M., Altraif, I., Duberg, A.-S., Muljono, D. H., Waked, I., Alavian, S. M., Lee, M.-H., Negro, F., Abaalkhail, F., Abdou, A., Abdulla, M., Rached, A. A., Aho, I., Akarca, U., Al Ghazzawi, I., Al Kaabi, S., Al Lawati, F., … Razavi, H. (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. The Lancet Gastroenterology & Hepatology, 2(3), 161–176. https://doi.org/https://doi.org/10.1016/S2468-1253(16)30181-9
- Boonma, T., Nutho, B., Rungrotmongkol, T., & Nunthaboot, N. (2019). Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective. Computational Biology and Chemistry, 83(November), 107154. https://doi.org/https://doi.org/10.1016/j.compbiolchem.2019.107154
- Brooks, B., & Karplus, M. (1983). Harmonic dynamics of proteins: Normal modes and fluctuations in bovine pancreatic trypsin inhibitor (vibrational analysis/protein dynamics/temperature factors/thermodynamic properties/frequency spectrum). Proceedings of the National Academy of Sciences, 80(21), 6571–6575. https://doi.org/https://doi.org/10.1073/pnas.80.21.6571
- Case, D. A., Betz, R. M., Cerutti, D. S., T. E., C. I., Darden, T. A., Duke, R. E., & Kollman, P. A. (2016). Amber 2016. University of California.
- Courcambeck, J., Bouzidi, M., Perbost, R., Jouirou, B., Amrani, N., Cacoub, P., Pèpe, G., Sabatier, J.-M., & Halfon, P. (2006). Resistance of hepatitis C virus to NS3-4A protease inhibitors: Mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Antiviral Therapy, 11(7), 847–855.
- Cummings, M. D., Lindberg, J., Lin, T.-I., de Kock, H., Lenz, O., Lilja, E., Felländer, S., Baraznenok, V., Nyström, S., Nilsson, M., Vrang, L., Edlund, M., Rosenquist, A., Samuelsson, B., Raboisson, P., & Simmen, K. (2010). Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. Angewandte Chemie (International ed. in English), 49(9), 1652–1655. https://doi.org/https://doi.org/10.1002/anie.200906696
- Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems. The Journal of Chemical Physics, 98(12), 10089–10092. https://doi.org/https://doi.org/10.1063/1.464397
- De Luca, A., Bianco, C., & Rossetti, B. (2014). Treatment of HCV infection with the novel NS3/4A protease inhibitors. Current Opinion in Pharmacology, 18, 9–17. https://doi.org/https://doi.org/10.1016/j.coph.2014.07.016
- Elstner, M. (2006). The SCC-DFTB method and its application to biological systems. Theoretical Chemistry Accounts, 116(1–3), 316–325. https://doi.org/https://doi.org/10.1007/s00214-005-0066-0
- Ezat, A. A., El-Bialy, N. S., Mostafa, H. I. A., & Ibrahim, M. A. (2014). Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V). The Protein Journal, 33(1), 32–47. https://doi.org/https://doi.org/10.1007/s10930-013-9538-6
- Ezat, A. A., & Elshemey, W. M. (2019). A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches. Life Sciences, 217, 176–184. https://doi.org/https://doi.org/10.1016/j.lfs.2018.12.004
- Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017). Oral direct-acting agent therapy for hepatitis c virus infection: A systematic review. Annals of Internal Medicine, 166(9), 637–648. https://doi.org/https://doi.org/10.7326/M16-2575
- Frecer, V., Kabeláč, M., De Nardi, P., Pricl, S., & Miertuš, S. (2004). Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus. Journal of Molecular Graphics & Modelling, 22(3), 209–220. https://doi.org/https://doi.org/10.1016/S1093-3263(03)00161-X
- Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., Scalmani, G., Barone, V., Mennucci, B., Petersson, G. A., Nakatsuji, H., Caricato, M., Li, X., Hratchian, H. P., Izmaylov, A. F., Bloino, J., Zheng, G., Sonnenberg, J. L., Hada, M., … Fox, D. J. (2009). Gaussian 09. Gaussian, Inc.
- Fu, J., & Wei, J. (2015). Molecular dynamics study on drug resistance mechanism of HCV NS3/4A protease inhibitor: BI201335. Molecular Simulation, 41(8), 674–682. https://doi.org/https://doi.org/10.1080/08927022.2014.917298
- Halfon, P., & Locarnini, S. (2011). Hepatitis C virus resistance to protease inhibitors. Journal of Hepatology, 55(1), 192–206. https://doi.org/https://doi.org/10.1016/j.jhep.2011.01.011
- He, Y., King, M. S., Kempf, D. J., Lu, L., Lim, H. B., Krishnan, P., Kati, W., Middleton, T., & Molla, A. (2008). Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrobial Agents and Chemotherapy, 52(3), 1101–1110. https://doi.org/https://doi.org/10.1128/AAC.01149-07
- Jiang, Y., Andrews, S. W., Condroski, K. R., Buckman, B., Serebryany, V., Wenglowsky, S., Kennedy, A. L., Madduru, M. R., Wang, B., Lyon, M., Doherty, G. A., Woodard, B. T., Lemieux, C., Geck Do, M., Zhang, H., Ballard, J., Vigers, G., Brandhuber, B. J., Stengel, P., … Seiwert, S. D. (2014). Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. Journal of Medicinal Chemistry, 57(5), 1753–1769. https://doi.org/https://doi.org/10.1021/jm400164c
- Jorgensen, W. L., Tirado-Rives, J., & Fields, F. (2005). Potential energy functions for atomic-level simulations of water and organic and biomolecular systems. Proceedings of the National Academy of Sciences, 102(19), 1–6. https://doi.org/https://doi.org/10.1073/pnas.0408037102
- Kammarabutr, J., Mahalapbutr, P., Nutho, B., Kungwan, N., & Rungrotmongkol, T. (2019). Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation. Journal of Molecular Graphics and Modelling, 89, 122–130. https://doi.org/https://doi.org/10.1016/j.jmgm.2019.03.006
- Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., Lee, M., Lee, T., Duan, Y., Wang, W., Donini, O., Cieplak, P., Srinivasan, J., Case, D. A., & Cheatham, T. E. (2000). Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Accounts of Chemical Research, 33(12), 889–897. https://doi.org/https://doi.org/10.1021/ar000033j
- Kwo, P. Y., Poordad, F., Asatryan, A., Wang, S., Wyles, D. L., Hassanein, T., Felizarta, F., Sulkowski, M. S., Gane, E., Maliakkal, B., Overcash, J. S., Gordon, S. C., Muir, A. J., Aguilar, H., Agarwal, K., Dore, G. J., Lin, C.-W., Liu, R., Lovell, S. S., … Mensa, F. J. (2017). Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. Journal of Hepatology, 67(2), 263–271. https://doi.org/https://doi.org/10.1016/j.jhep.2017.03.039
- Maier, J. A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K. E., & Simmerling, C. (2015). ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. Journal of Chemical Theory and Computation, 11(8), 3696–3713. https://doi.org/https://doi.org/10.1021/acs.jctc.5b00255
- Matthew, A. N., Leidner, F., Newton, A., Petropoulos, C. J., Huang, W., Ali, A., KurtYilmaz, N., & Schiffer, C. A. (2018). Molecular mechanism of resistance in a clinically significant double-mutant variant of HCV NS3/4A protease. Structure (London, England: 1993), 26(10), 1360–1372.e5. https://doi.org/https://doi.org/10.1016/j.str.2018.07.004
- Matthew, A. N., Zephyr, J., Hill, C. J., Jahangir, M., Newton, A., Petropoulos, C. J., Huang, W., Kurt-Yilmaz, N., Schiffer, C. A., & Ali, A. (2017). Hepatitis C virus NS3/4A protease inhibitors incorporating flexible P2 quinoxalines target drug resistant viral variants. Journal of Medicinal Chemistry, 60(13), 5699–5716. https://doi.org/https://doi.org/10.1021/acs.jmedchem.7b00426
- McCauley, J. A., & Rudd, M. T. (2016). Hepatitis C virus NS3/4a protease inhibitors. Current Opinion in Pharmacology, 30, 84–92. https://doi.org/https://doi.org/10.1016/j.coph.2016.07.015
- Meeprasert, A., Hannongbua, S., Kungwan, N., & Rungrotmongkol, T. (2016). Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir. Molecular Biosystems, 12(12), 3666–3673. https://doi.org/https://doi.org/10.1039/c6mb00610h
- Meeprasert, A., Hannongbua, S., & Rungrotmongkol, T. (2014). Key binding and susceptibility of NS3/4A serine protease inhibitors against hepatitis C virus. Journal of Chemical Information and Modeling, 54(4), 1208–1217.
- Mensa, F. J., Lovell, S., Pilot-Matias, T., & Liu, W. (2019). Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiology, 14(2), 89–110. https://doi.org/https://doi.org/10.2217/fmb-2018-0233
- Miller, B. R., McGee, T. D., Swails, J. M., Homeyer, N., Gohlke, H., & Roitberg, A. E. (2012). MMPBSA.py: An efficient program for end-state free energy calculations. Journal of Chemical Theory and Computation, 8(9), 3314–3321. https://doi.org/https://doi.org/10.1021/ct300418h
- Mishra, S. K., & Koča, J. (2018). Assessing the performance of MM/PBSA, MM/GBSA, and QM-MM/GBSA approaches on protein/carbohydrate complexes: Effect of implicit solvent models, QM methods, and entropic contributions. The Journal of Physical Chemistry. B, 122(34), 8113–8121. https://doi.org/https://doi.org/10.1021/acs.jpcb.8b03655
- Miyamoto, S., & Kollman, P. A. (1992). Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models. Journal of Computational Chemistry, 13(8), 952–962. https://doi.org/https://doi.org/10.1002/jcc.540130805
- Ng, T. I., Tripathi, R., Reisch, T., Lu, L., Middleton, T., Hopkins, T. A., Pithawalla, R., Irvin, M., Dekhtyar, T., Krishnan, P., Schnell, G., Beyer, J., McDaniel, K. F., Ma, J., Wang, G., Jiang, L.-J., Or, Y. S., Kempf, D., Pilot-Matias, T., & Collins, C. (2017). In vitro antiviral activity and resistance profile of the next-generation HCV NS3-4A protease inhibitor glecaprevir. Antimicrobial Agents and Chemotherapy, 62(1), 1–16. https://doi.org/https://doi.org/10.1128/AAC.01620-17
- Nutho, B., Khuntawee, W., Rungnim, C., Pongsawasdi, P., Wolschann, P., Karpfen, A., Kungwan, N., & Rungrotmongkol, T. (2014). Binding mode and free energy prediction of fisetin/β-cyclodextrin inclusion complexes. Beilstein Journal of Organic Chemistry, 10, 2789–2799. https://doi.org/https://doi.org/10.3762/bjoc.10.296
- Nutho, B., Meeprasert, A., Chulapa, M., Kungwan, N., & Rungrotmongkol, T. (2017). Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: A steered molecular dynamics. Journal of Biomolecular Structure & Dynamics, 35(8), 1743–1757. https://doi.org/https://doi.org/10.1080/07391102.2016.1193444
- Onufriev, A., Bashford, D., & Case, D. A. (2004). Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins, 55(2), 383–394. https://doi.org/https://doi.org/10.1002/prot.20033
- Özen, A., Prachanronarong, K., Matthew, A. N., Soumana, D. I., & Schiffer, C. A. (2019). Resistance outside the substrate envelope: Hepatitis C NS3/4A protease inhibitors. Critical Reviews in Biochemistry and Molecular Biology, 54(1), 11–26. https://doi.org/https://doi.org/10.1080/10409238.2019.1568962
- Palanisamy, N., & Lennerstrand, J. (2018). Biophysical studies on HCV 1a NS3/4A protease and its catalytic triad in wild type and mutants by the in silico approach. Interdisciplinary Sciences, Computational Life Sciences, 10(1), 143–156. https://doi.org/https://doi.org/10.1007/s12539-016-0177-4
- Pan, D., Xue, W., Zhang, W., Liu, H., & Yao, X. (2012). Understanding the drug resistance mechanism of hepatitis C virus NS3/4A to ITMN-191 due to R155K, A156V, D168A/E mutations: A computational study. Biochimica et Biophysica Acta, 1820(10), 1526–1534. https://doi.org/https://doi.org/10.1016/j.bbagen.2012.06.001
- Pilot-Matias, T., Tripathi, R., Cohen, D., Gaultier, I., Dekhtyar, T., Lu, L., Reisch, T., Irvin, M., Hopkins, T., Pithawalla, R., Middleton, T., Ng, T., McDaniel, K., Or, Y. S., Menon, R., Kempf, D., Molla, A., & Collins, C. (2015). In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrobial Agents and Chemotherapy, 59(2), 988–997. https://doi.org/https://doi.org/10.1128/AAC.04227-14
- Romano, K. P., Ali, A., Aydin, C., Soumana, D., Özen, A., Deveau, L. M., Silver, C., Cao, H., Newton, A., Petropoulos, C. J., Huang, W., & Schiffer, C. A. (2012). The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathogens, 8(7), e1002832. https://doi.org/https://doi.org/10.1371/journal.ppat.1002832
- Romano, K. P., Ali, A., Royer, W. E., & Schiffer, C. A. (2010). Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proceedings of the National Academy of Sciences of the United States of America, 107(49), 20986–20991. https://doi.org/https://doi.org/10.1073/pnas.1006370107
- Rusere, L. N., Matthew, A. N., Lockbaum, G. J., Jahangir, M., Newton, A., Petropoulos, C. J., Huang, W., Kurt Yilmaz, N., Schiffer, C. A., & Ali, A. (2018). Quinoxaline-based linear HCV NS3/4A protease inhibitors exhibit potent activity against drug resistant variants. ACS Medicinal Chemistry Letters, 9(7), 691–696. https://doi.org/https://doi.org/10.1021/acsmedchemlett.8b00150
- Sandhiya, R., Dayshy, A. R., Shanthi, V., & Ramanathan, K. (2013). Investigation of MK-5172 resistance against R155K NS3/4A protease by molecular simulation approach. Der Pharmacia Lettre, 5(3), 13–20.
- Sitkoff, D., Sharp, K. A., & Honig, B. (1994). Accurate calculation of hydration free energies using macroscopic solvent models. The Journal of Physical Chemistry, 98(7), 1978–1988. https://doi.org/https://doi.org/10.1021/j100058a043
- Sorbo, M. C., Cento, V., Di Maio, V. C., Howe, A. Y. M., Garcia, F., Perno, C. F., & Ceccherini-Silberstein, F. (2018). Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resistance Updates, 37(January), 17–39. https://doi.org/https://doi.org/10.1016/j.drup.2018.01.004
- Soumana, D. I., Kurt Yilmaz, N., Ali, A., Prachanronarong, K. L., & Schiffer, C. A. (2016a). Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3/4A protease. Journal of the American Chemical Society, 138(36), 11850–11859. https://doi.org/https://doi.org/10.1021/jacs.6b06454
- Soumana, D. I., Kurt Yilmaz, N., Prachanronarong, K. L., Aydin, C., Ali, A., & Schiffer, C. A. (2016b). Structural and thermodynamic effects of macrocyclization in HCV NS3/4A inhibitor MK-5172. ACS Chemical Biology, 11(4), 900–909. https://doi.org/https://doi.org/10.1021/acschembio.5b00647
- Stote, R. H., & Karplus, M. (1995). Zinc binding in proteins and solution: A simple but accurate nonbonded representation. Proteins, 23(1), 12–31. https://doi.org/https://doi.org/10.1002/prot.340230104
- Taylor, J. G., Zipfel, S., Ramey, K., Vivian, R., Schrier, A., Karki, K. K., Katana, A., Kato, D., Kobayashi, T., Martinez, R., Sangi, M., Siegel, D., Tran, C. V., Yang, Z.-Y., Zablocki, J., Yang, C. Y., Wang, Y., Wang, K., Chan, K., … Link, J. O. (2019). Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®. Bioorganic & Medicinal Chemistry Letters, 29(16), 2428–2436. https://doi.org/https://doi.org/10.1016/j.bmcl.2019.03.037
- Timm, J., Kosovrasti, K., Henes, M., Leidner, F., Hou, S., Ali, A., Kurt Yilmaz, N., & Schiffer, C. A. (2020). Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir. ACS Chemical Biology, 15(2), 342–352. https://doi.org/https://doi.org/10.1021/acschembio.9b00675
- Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general Amber force field. Journal of Computational Chemistry, 25(9), 1157–1174. https://doi.org/https://doi.org/10.1002/jcc.20035
- Xue, W., Ban, Y., Liu, H., & Yao, X. (2014). Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis. Journal of Chemical Information and Modeling, 54(2), 621–633. https://doi.org/https://doi.org/10.1021/ci400060j
- Xue, W., Pan, D., Yang, Y., Liu, H., & Yao, X. (2012). Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. Antiviral Research, 93(1), 126–137. https://doi.org/https://doi.org/10.1016/j.antiviral.2011.11.007
- Yang, Z., Lasker, K., Schneidman-Duhovny, D., Webb, B., Huang, C. C., Pettersen, E. F., Goddard, T. D., Meng, E. C., Sali, A., & Ferrin, T. E. (2012). UCSF Chimera, MODELLER, and IMP: An integrated modeling system. Journal of Structural Biology, 179(3), 269–278. https://doi.org/https://doi.org/10.1016/j.jsb.2011.09.006
- Zając, M., Muszalska, I., Sobczak, A., Dadej, A., Tomczak, S., & Jelińska, A. (2019). Hepatitis C - New drugs and treatment prospects. European Journal of Medicinal Chemistry, 165, 225–249. https://doi.org/https://doi.org/10.1016/j.ejmech.2019.01.025